Activity of Decitabine in Patients with Myelodysplastic Syndrome Previously Treated with Azacitidine

BACKGROUND: Azacitidine and decitabine are two hypomethylating agents approved by the Food and Drug Administration for the treatment of patients with myelodysplastic syndrome (MDS). The efficacy of one agent post failure of the other is unknown. METHODS: Fourteen patients with MDS post azacitidine f...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Borthakur, Gautam, El Ahdab, Samih Y., Garcia-Manero, Guillermo, Ravandi, Farhad, Ferrajoli, Alessandra, Newman, Beth A, Issa, Jean-Pierre, Kantarjian, Hagop
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2008
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3702160/
https://ncbi.nlm.nih.gov/pubmed/18398735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428190701882146
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller